ESR1 and breast cancer: The initial preclinical reports of the activity of fulvestrant (ICI 182,780) described a compound with promise as a mechanistically novel approach to targeting ER activity in breast cancer, and indeed, in most preclinical models fulvestrant exhibited efficacy under conditions in which other contemporary drugs (e.g., tamoxifen, raloxifene, toremifene) were ineffective.